Current Problems in Cardiology最新文献_第5页

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-28 DOI: 10.1016/S0146-2806(25)00156-2

引用次数: 0

Erratum to “Selexipag in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials” [Current Problems in Cardiology 48(2023) 101466] “Selexipag在肺动脉高压患者中的应用：随机对照试验的系统评价和荟萃分析”[contemporary Problems in Cardiology] 48(2023) 101466]。

IF 3.3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-28 DOI: 10.1016/j.cpcardiol.2025.103127

Jinlv Qin , Guizuo Wang , Dong Han

引用次数: 0

Guidelines for Authors 作者指南

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-28 DOI: 10.1016/S0146-2806(25)00162-8

引用次数: 0

Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy Tafamidis：促甲状腺素型心肌病的游戏规则改变者？安全性和有效性的系统评价和荟萃分析。

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-18 DOI: 10.1016/j.cpcardiol.2025.103129

Bilal Hussain MD , Sanchit Duhan MBBS , Bansari Patel MD , Yu-Chun Chang MS3 PhD , Mohammad Hamza MD , Maria Najam MD , Mustafa Sajjad Cheema MD , Mubashar Karamat MD , Junaid Mir MD , Bijeta Keisham MD , M. Chadi Alraies MD , Yasar Sattar MD

{"title":"Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy","authors":"Bilal Hussain MD , Sanchit Duhan MBBS , Bansari Patel MD , Yu-Chun Chang MS3 PhD , Mohammad Hamza MD , Maria Najam MD , Mustafa Sajjad Cheema MD , Mubashar Karamat MD , Junaid Mir MD , Bijeta Keisham MD , M. Chadi Alraies MD , Yasar Sattar MD","doi":"10.1016/j.cpcardiol.2025.103129","DOIUrl":"10.1016/j.cpcardiol.2025.103129","url":null,"abstract":"<div><h3>Purpose</h3><div>Tafamidis was FDA-approved for Transthyretin cardiomyopathy (ATTR-CM) due to its demonstrated reduction in mortality and hospitalizations.</div></div><div><h3>Methods</h3><div>976 studies from PubMed and Embase were screened. Seven studies were included that compared tafamidis treatment with no tafamidis for ATTR-CM. The mantel-Haenszel method was used for binary outcomes, and Hedges’ g was used for continuous outcomes.</div></div><div><h3>Results</h3><div>Tafamidis was associated with decreased odds of mortality (OR 0.55, 95 % CI 0.42-0.73, I<sup>2</sup>=41 %, p<0.0001) and reduced CHF exacerbations (OR 0.71, 95 % CI 0.51-0.99, I<sup>2</sup>= 0 %, p= 0.04). While, CHF related hospitalizations (OR 0.35, 95 % CI 0.07-1.67, I2= 87 %, p= 0.19), atrial arrhythmias (OR 0.98, 95 % CI 0.67-1.42, I<sup>2</sup>= 0 %, p= 0.9), change in left ventricular ejection fraction (SMD 0.87, 95 % CI -0.37-2.11, I<sup>2</sup>=98 %, p= 0.17), left ventricular end-diastolic diameter from baseline (SMD -0.12, 95 % CI -0.41-0.18, I<sup>2</sup>= 0 %, p= 0.4), interventricular septal thickness from baseline (SMD -0.7, 95 % CI -1.57-0.17, I<sup>2</sup>= 96 %, p= 0.11) were not statistically different for tafamidis compared to no tafamidis for ATTR-CM.</div></div><div><h3>Conclusion</h3><div>Tafamidis treatment in ATTR-CM is associated with reduced all-cause mortality and a lower incidence of CHF exacerbations. These observations are consistent with the ATTRACT trial, which supports the efficacy of tafamidis in treating ATTR-CM.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 9","pages":"Article 103129"},"PeriodicalIF":3.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure with microvascular dysfunction: Insights from a propensity-matched analysis of diabetic retinopathy in heart failure with reduced ejection fraction 心力衰竭伴微血管功能障碍：来自糖尿病视网膜病变伴射血分数降低心力衰竭倾向匹配分析的见解。

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-18 DOI: 10.1016/j.cpcardiol.2025.103128

Silvio Nunes Augusto Jr , Rochell Issa MD , David Kaelber MD PhD MPH , W.H. Wilson Tang MD

{"title":"Heart failure with microvascular dysfunction: Insights from a propensity-matched analysis of diabetic retinopathy in heart failure with reduced ejection fraction","authors":"Silvio Nunes Augusto Jr , Rochell Issa MD , David Kaelber MD PhD MPH , W.H. Wilson Tang MD","doi":"10.1016/j.cpcardiol.2025.103128","DOIUrl":"10.1016/j.cpcardiol.2025.103128","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic retinopathy, a microvascular complication of diabetes, is a significant marker of systemic vascular damage, which has been linked to increased cardio-renal disease risks. This study investigates the impact of diabetic retinopathy on all-cause mortality and adverse cardiovascular and renal outcomes in patients with established heart failure with reduced ejection fraction (HFrEF) using real-world data.</div></div><div><h3>Methods</h3><div>Using data from January 1, 2012, to December 31, 2021, we conducted a propensity-matched analysis of two cohorts of patients with HFrEF and diabetes without chronic kidney disease (CKD, estimated glomerular filtration rate >60 mL/min/1.73 m²), differentiated by the presence or absence of diabetic retinopathy diagnosis in the TriNetX platform. The primary outcome was all-cause mortality, with secondary outcomes including acute HF, CKD progression, major adverse cardiovascular events, stroke, in-patient hospitalizations, venous thromboembolism (VTE), and peripheral arterial disease (PAD).</div></div><div><h3>Results</h3><div>Following propensity score matching across demographics and clinical variables, each cohort included 15,218 patients. Acute HF was more common in the retinopathy vs non-retinopathy cohort (HR: 1.13, 95 % CI: 1.06–1.20). Results also showed significant increased risks for CKD progression (HR: 1.39, 95 % CI: 1.30–1.50), stroke (HR: 1.18, 95 % CI: 1.08–1.28), as well as PAD (HR: 1.58, 95 % CI: 1.42–1.76) for patients with diabetic retinopathy.</div></div><div><h3>Conclusion</h3><div>Diabetic retinopathy is associated with an increased risk of adverse cardio-renal outcomes in patients with established HFrEF.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 10","pages":"Article 103128"},"PeriodicalIF":3.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of implementation of follow-up care model on self-management in patient with chronic heart failure disease 实施随访护理模式对慢性心力衰竭患者自我管理的影响

IF 3.3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-01 DOI: 10.1016/j.cpcardiol.2025.103120

Mohammed Khanjary MSc, Shokoh Varaei PhD, Haitham Ibrahim Faris PhD

引用次数: 0

Atherosclerosis and sudden cardiac death in athletes 动脉粥样硬化与运动员心源性猝死

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-01 DOI: 10.1016/j.cpcardiol.2025.103123

Lweendo Muchaili , Situmbeko Liweleya , Lukundo Siame , John Nzobokela , Boas Machacha , Elletina N. Sinamwenda , Cindy Manjesani , Bislom Chikwanka Mweene , Benson M. Hamooya , Sepiso K. Masenga

{"title":"Atherosclerosis and sudden cardiac death in athletes","authors":"Lweendo Muchaili , Situmbeko Liweleya , Lukundo Siame , John Nzobokela , Boas Machacha , Elletina N. Sinamwenda , Cindy Manjesani , Bislom Chikwanka Mweene , Benson M. Hamooya , Sepiso K. Masenga","doi":"10.1016/j.cpcardiol.2025.103123","DOIUrl":"10.1016/j.cpcardiol.2025.103123","url":null,"abstract":"<div><div>Asymptomatic atherosclerotic cardiovascular disease (ASCVD) is the leading cause of sudden cardiac death (SCD) in athletes over 35 years of age. Despite their high physical fitness, athletes in this age group remain vulnerable to undetected coronary atherosclerosis, which predisposes them to plaque rupture and acute coronary thrombosis. In contrast, congenital coronary anomalies are the predominant cause of SCD in younger athletes. While SCD accounts for over 90 % of sports-related cardiovascular mortality, identifying at-risk individuals remains challenging due to the silent progression of coronary artery disease (CAD). Current screening methods, such as electrocardiography and stress testing, have limited sensitivity for detecting asymptomatic ASCVD, underscoring the need for advanced imaging modalities like coronary computed tomography angiography (CCTA) in high-risk populations. Risk mitigation requires a multifaceted approach: Tailored pre-participation cardiovascular screening incorporating age-specific risk factors, lifestyle interventions targeting atherosclerosis progression, education for early recognition of cardiac symptoms, and widespread availability of automated external defibrillators (AEDs) during athletic events. Emerging evidence supports integrating biomarkers, for instance, coronary calcium scoring and genetic testing for congenital anomalies, to enhance risk stratification. A comprehensive strategy combining targeted screening, advanced diagnostics, and evidence-based interventions is critical to reducing SCD incidence and improving outcomes in athletes.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 9","pages":"Article 103123"},"PeriodicalIF":3.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and clinical outcomes in malignant phase hypertension patients using cluster analysis: A report from the West Birmingham Malignant Hypertension Registry 使用聚类分析的恶性期高血压患者的特征和临床结果：一份来自西伯明翰恶性高血压登记处的报告

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-06-30 DOI: 10.1016/j.cpcardiol.2025.103121

Antonios A. Argyris , Alena Shantsila , Eduard Shantsila , D. Gareth Beevers , Gregory Y.  H. Lip

{"title":"Characteristics and clinical outcomes in malignant phase hypertension patients using cluster analysis: A report from the West Birmingham Malignant Hypertension Registry","authors":"Antonios A. Argyris , Alena Shantsila , Eduard Shantsila , D. Gareth Beevers , Gregory Y.  H. Lip","doi":"10.1016/j.cpcardiol.2025.103121","DOIUrl":"10.1016/j.cpcardiol.2025.103121","url":null,"abstract":"<div><h3>Purpose</h3><div>Malignant hypertension (MHT) is a condition with high morbidity and mortality, necessitating a deeper understanding of its clinical heterogeneity for improved patient management. Aim of our study was to identify/characterize specific phenotypic groups and examine their associations with mortality.</div></div><div><h3>Methods</h3><div>Data from the West Birmingham MHT Registry were used. We performed two-step cluster analysis to determine distinct groups. Kaplan-Meier curves and Cox proportional hazard models were used to examine the associations of clusters with mortality.</div></div><div><h3>Results</h3><div>323 patients (mean age 49±13 years; 34 % female) with a median follow-up of 11 (IQR 3-18) years were included. Four clusters were identified; Cluster 1: younger age, intermediate prevalence of cardiovascular risk factors, high prevalence of renal/retinal damage; Cluster 2: older age, female, low prevalence of cardiovascular risk factors, intermediate levels of organ damage; Cluster 3: intermediate age, male, high prevalence of cardiovascular risk factors, high retinal damage; Cluster 4: younger age, male, low prevalence of cardiovascular risk factors, low prevalence of organ damage. In Kaplan Meier curves cluster 4 exhibited the lowest risk, while cluster 3 the highest risk for outcomes (log rank <em>p</em> < 0.001). In Cox regression, all clusters had higher risk of mortality compared to cluster 4; cluster 1 [HR 1.74 (1.07-2.82)], cluster 2 [HR 1.87 (1.20-2.91)], cluster 3 [HR 2.35 (1.54-3.58)].</div></div><div><h3>Conclusions</h3><div>Four distinct phenotypic clusters were identified within our registry, having diverse associations with mortality. These clusters offer a framework for more targeted risk stratification and prognostication, with implications for individualized patient care in this high-risk hypertensive population.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 9","pages":"Article 103121"},"PeriodicalIF":3.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144522655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Information for Readers 读者资讯

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-06-30 DOI: 10.1016/S0146-2806(25)00133-1

引用次数: 0

Guidelines for Authors 作者指南

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-06-30 DOI: 10.1016/S0146-2806(25)00138-0

引用次数: 0